Top 5 Most Read RNS's on Vox Markets for Thursday 22nd September 2022
Episode 910, Sep 22, 2022, 08:02 AM
Top 5 Most Read RNS's on Vox Markets for Thursday 22nd September 2022
5. i3 Energy #I3E - Serenity Appraisal Well Spud.
Is pleased to announce the spud of the Serenity appraisal well on UK Licence P.2358, Block 13/23c. i3 owns a 75% working interest in the field.
4. Mobile Streams #MOS - Mobile Streams signs NFT contract with Atlante FC
Announce it has signed a 5-year contract to be the exclusive provider of all NFT products for Atlante Football club
3. Deepverge #DVRG - Interim Results
H1 revenues grew by 94% to £6.44m (2021 H1: £3.32m) with expected full year revenues weighted to H2.
2. Supply @ME Capital #SYME - Exercise of Warrants, Issue of Equity and TVR
1. Polarean Imaging #POLX - Update on New Drug Application
Update on New Drug Application - FDA request for additional information from Polarean's contract drug manufacturer.
The FDA has suggested that the required information would constitute a major amendment to the New Drug Application ("NDA") that, if timely submitted, would allow for the FDA to grant a 90-day extension to the review timeline.
5. i3 Energy #I3E - Serenity Appraisal Well Spud.
Is pleased to announce the spud of the Serenity appraisal well on UK Licence P.2358, Block 13/23c. i3 owns a 75% working interest in the field.
4. Mobile Streams #MOS - Mobile Streams signs NFT contract with Atlante FC
Announce it has signed a 5-year contract to be the exclusive provider of all NFT products for Atlante Football club
3. Deepverge #DVRG - Interim Results
H1 revenues grew by 94% to £6.44m (2021 H1: £3.32m) with expected full year revenues weighted to H2.
2. Supply @ME Capital #SYME - Exercise of Warrants, Issue of Equity and TVR
1. Polarean Imaging #POLX - Update on New Drug Application
Update on New Drug Application - FDA request for additional information from Polarean's contract drug manufacturer.
The FDA has suggested that the required information would constitute a major amendment to the New Drug Application ("NDA") that, if timely submitted, would allow for the FDA to grant a 90-day extension to the review timeline.